Previous 10 | Next 10 |
Agios Pharmaceuticals ( AGIO +5% ) is up on light volume in early trade in response to updated data from a Phase 1 clinical trial evaluating TIBSOVO (ivosidenib), combined with Celgene's ( CELG +0.8% ) VIDAZA (azacitidine), for the first-line treatment of patients with IDH1 mutation-po...
Merger activity increased last week with four new deals announced and four pending deals closing. Deal Statistics: New Deals: The acquisition of Immune Design (IMDZ) by Merck (MRK) for $300 million or $5.85 per share in cash. The acquisition of Citizens First Corporation (C...
Bristol-Myers Squibb (NYSE: BMY ) has filed a proxy statement for the April 12 special shareholders meeting to vote on its planned merger with Celgene (NASDAQ: CELG ). More news on: Bristol-Myers Squibb Company, Celgene Corporation, Healthcare stocks news, Read more ...
In this episode of According to Sources, the Merger Masters series continues with an interview with John Paulson. He discusses his early career, choosing which deals to participate in, SKY Ltd, Comcast (CMCSA), Disney (DIS), hedge fund vs. family office, Bristol-Myers Squibb (BMY)/Celgene (C...
Takeover target Celgene ( CELG ) is a nerve-wracking long with all the talk of activist Starboard Value wanting to break it up. However, this situation is worth some aggravation. Bristol-Myers ( BMY ) is offering $50 in cash per Celgene share, 1 share of Bristol-Myers and a CVR (worth between ...
In this episode , host Michael Samuels revisits Barnes & Noble after mixed holiday sales and explains how he's adjusted his position in MLNX. He also discusses QEP & ARNC and the 6 factors driving the spread in BMY/CELG. BMY / CELG : 6 Factors Driving The Read more ...
According to the Centers for Medicare & Medicaid Services (CMS), U.S. healthcare spending is expected to rise 5.5% each year over the next decade, reaching ~$6T by 2027 (19.4% of GDP). More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Tr...
Bristol-Myers Squibb ( BMY -0.3% ) and Celgene ( CELG -0.1% ) are both off their intraday highs in the wake of reports that certain institutional shareholders, including Starboard Value and Dodge & Cox, lack enthusiasm for the planned merger. More news on: Bristol-Myers Squibb Co...
In its updated investor presentation detailing the advantages of its planned takeover of Celgene ( CELG +0.7% ), Bristol-Myers Squibb ( BMY +0.8% ) expects to generate ~$53B in revenues and over $20B in non-GAAP net income in 2025. More news on: Celgene Corporation, Bristol-Myers Squ...
In a statement , Bristol-Myers Squibb (NYSE: BMY ) says its takeover of Celgene (NASDAQ: CELG ) "remains on track" to close in Q3. More news on: Bristol-Myers Squibb Company, Celgene Corporation, Healthcare stocks news, Merger & acquisition news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Celgene Corporation Company Name:
CELG Stock Symbol:
NASDAQ Market:
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...
What coronavirus? Amgen 's (NASDAQ: AMGN) latest set of quarterly figures, delivered Tuesday, showed growth in the company's fundamentals during a challenging time for companies across all economic sectors. The veteran biotech company booked revenue of nearly $6.21 billion in the second qu...
It's scary out there right now for investors, with wild market swings and a lot of negative news coming out of quarterly reports. There is one sector, however, that will survive and likely thrive despite the coronavirus pandemic shutdown -- healthcare. That said, investors shouldn't head for jus...